Cempra Pharmaceuticals
Solithromycin, a next-generation macrolide antibiotic
- Sector
- Biotech
- Total capital
- $52.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $52.5M
- 1 award · Health and Human S
- Rank in Biotech#16 of 4373
- Granted patents
- 8
- 32 pending · first 2014
- Rank in peer group#196 of 1449
Capital timeline
Latest events
- Federal contractHealth and Human S · Cempra - Solithromycin (CEM-101) For Civilian Use And Broad Bioterror Threat Medical Countermeasures.$52.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#196 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 8 granted of 40- PendingCompositions and Methods for Treating Dry Eye DiseasesUSPTOApplication 16602279
- GrantedParenteral Formulations For Administering Macrolide AntibioticsUSPTOUS 10,188,674
- GrantedProcess For The Preparation Of Macrolide Antibacterial AgentsUSPTOUS 10,131,684
Show all 40 patent records
- Compositions and Methods for Treating Dry Eye DiseasesMay 13, 2021 · Application 16602279Pending
- Parenteral Formulations For Administering Macrolide AntibioticsJan 29, 2019 · US 10,188,674Granted
- Process For The Preparation Of Macrolide Antibacterial AgentsNov 20, 2018 · US 10,131,684Granted
- Methods For Treating Resistant Diseases Using Triazole Containing MacrolidesFeb 27, 2018 · US 9,901,592Granted
- 4-AZIDOBUTYLAMINES And Processes For PreparingJan 18, 2018 · Application 15548134Pending
- Methods For Treating Respiratory Diseases And Formulations ThereforJan 9, 2018 · US 9,861,616Granted
- Convergent Processes For Preparing Macrolide Antibacterial AgentsSep 5, 2017 · US 9,751,908Granted
- Powder Oral Suspension Formulations Of Antibacterial AgentsAug 10, 2017 · Application 15501516Pending
- Compositions And Methods For Treating Diabetes And Liver DiseasesJun 15, 2017 · Application 15118124Pending
- Biodefenses Using Triazole-containing MacrolidesJun 6, 2017 · US 9,669,046Granted
- Methods For Treating Gastrointestinal DiseasesSep 13, 2016 · US 9,439,918Granted
- Crystalline Forms Of A Macrolide, And Uses ThereforAug 25, 2016 · Application 14859736Pending
- Processes For Preparing Macrolides And Ketolides And Intermediates ThereforAug 20, 2015 · Application 14702004Pending
- Crystalline Forms Of A Macrolide, And Uses ThereforJun 24, 2014 · US 8,759,500Granted
- 4-AZIDOBUTYLAMINES And Processes For PreparingApplication 62112672Pending
- Crystalline Forms Of A Macrolide, And Uses ThereforApplication 14611653Pending
- Compositions And Methods For Treating Diabetes And Liver And Fibrotic DiseasesApplication 62086911Pending
- Pediatric Formulations Of Antibacterial AgentsApplication 62033601Pending
- Compositions And Methods For Treating Liver And Fibrotic DiseasesApplication 61984225Pending
- Convergent Processes For Preparing Macrolide Antibacterial AgentsApplication PCTUS2014029932Pending
- Methods For Treating Respiratory Diseases And Formulations ThereforApplication PCTUS2014027214Pending
- Compositions And Methods For Treating Liver And Fibrotic DiseasesApplication 61939961Pending
- Parenteral Formulations For Administering Macrolide AntibioticsApplication PCTUS2013034179Pending
- Convergent Process For The Preparation Of Macrolide Antibacterial AgentsApplication 61786914Pending
- Parenteral Formulations For Administering Macrolide AntibioticsApplication 61783026Pending
- Methods For Treating Respiratory Diseases And Formulations ThereforApplication 61781197Pending
- Hydrogen Bond Forming Fluoro Ketolides For Treating DiseasesApplication PCTUS2011051064Pending
- Methods Of Treating Bacterial Infections Through Pulmonary Delivery Of Fusidic AcidApplication PCTUS2011047771Pending
- Processes For Preparing Macrolides And Ketolides And Intermediates ThereforApplication PCTUS2011037330Pending
- Crystalline Forms Of A Macrolide, And Uses ThereforApplication PCTUS2011029424Pending
- Methods Of Treating Malaria, Tuberculosis And Mac DeseasesApplication PCTUS2010048540Pending
- Methods For Treating Resistant Diseases Using Triazole Containing MacrolidesApplication PCTUS2009061977Pending
- Biodefenses Using Triazole-containing MacrolidesApplication PCTUS2009061978Pending
- Methods For Treating Gastrointestinal DiseasesApplication PCTUS2009061976Pending
- Fusidic Acid Dosing Regimens For Treatment Of Bacterial InfectionsApplication PCTUS2009050353Pending
- Process For The Preparation Of Macrolide Antibacterial AgentsApplication PCTUS2008080936Pending
- Compositions And Methods For Treating Dry Eye DiseasesApplication PCTUS2018021304Pending
- Triazole-containing Macrolides And Ophthalmic Uses ThereforApplication PCTUS2018018523Pending
- Processes For Preparing FluoroketolidesApplication PCTUS2017049871Pending
- Convergent Processes For Preparing Macrolide Antibacterial AgentsApplication 15665652Pending
Related companies, and why
- CRESTONE, INC.Similar federal contract value in Biotech · $61.5M in contracts
- Cidara TherapeuticsSimilar federal contract value in Biotech · $58.1M in contracts
- 3D SystemsSimilar federal contract value in Biotech · $52.7M in contracts
- Invirsa, Inc.Similar federal contract value in Biotech · $48M in contracts
- OPHIREX, INCSimilar federal contract value in Biotech · $46.2M in contracts
- METABOLON, INC.Similar federal contract value in Biotech · $42M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .